Fatigue and health-related quality of life assessment in patients with multiple sclerosis
Over the 4-month period, we monitored 51 patients with multiple sclerosis (MS), age 20-65. 83% of the monitored patients had relapse-remitting MS.
The patients were supplemented with 500mg of carnosine given in Karnozin Extra capsules.
We used two questionnaires to assess the effect of the supplementation – Multidimensional Fatigue Inventory (MFI) and a validated Health-related Quality of Life (HRQoL) questionnaire Short Form Survey Instrument 36 (SF-36).
We observed improvements in both scales, with a significant effect on physical and cognitive fatigue accompanied by improved HRQoL. Supplementation with Karnozine extra significantly reduced general fatigue, but also physical, cognitive and psychosocial fatigue. Patients feel better, sleep better and report increase strength and less exhaustion while doing everyday activities.
This study indicates that carnosine presents an important aspect of adjuvant therapy in patients with MS.
We are proud that these important findings are presented at the XXIV World Congress of Neurology among the respected experts in the diagnosis and treatment of MS and is published in the Journal of neurological sciences.
You can find full research here.